GenSight Biologics
Market Cap
€34.9m
Last Updated
2019/11/19 22:00 UTC
Data Sources
Company Financials +
Executive Summary
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
Snowflake
Fundamentals
Mediocre balance sheet with limited growth.
Share Price & News
How has GenSight Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SIGHT has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
11.8%
SIGHT
-3.9%
FR Biotechs
0.02%
FR Market
1 Year Return
-51.0%
SIGHT
-33.9%
FR Biotechs
18.9%
FR Market
Return vs Industry: SIGHT underperformed the French Biotechs industry which returned -33.9% over the past year.
Return vs Market: SIGHT underperformed the French Market which returned 18.9% over the past year.
Shareholder returns
| SIGHT | Industry | Market | |
|---|---|---|---|
| 7 Day | 11.8% | -3.9% | 0.02% |
| 30 Day | 3.4% | 4.1% | 4.7% |
| 90 Day | -13.7% | -13.3% | 7.3% |
| 1 Year | -51.0%-51.0% | -33.8%-33.9% | 22.9%18.9% |
| 3 Year | -84.5%-84.5% | -60.0%-60.0% | 49.5%35.3% |
| 5 Year | n/a | -62.5%-63.0% | 66.7%43.1% |
Price Volatility Vs. Market
How volatile is GenSight Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Do Institutions Own GenSight Biologics S.A. (EPA:SIGHT) Shares?1 month ago | Simply Wall St
Is GenSight Biologics S.A.'s (EPA:SIGHT) CEO Being Overpaid?3 months ago | Simply Wall St
Imagine Owning GenSight Biologics (EPA:SIGHT) And Trying To Stomach The 82% Share Price DropValuation
Is GenSight Biologics undervalued compared to its fair value and its price relative to the market?
2.27x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SIGHT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SIGHT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SIGHT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SIGHT is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SIGHT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SIGHT is overvalued based on its PB Ratio (2.3x) compared to the FR Biotechs industry average (1.9x).
Next Steps
Future Growth
How is GenSight Biologics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
-1.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SIGHT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SIGHT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SIGHT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SIGHT's revenue (39.1% per year) is forecast to grow faster than the French market (4.6% per year).
High Growth Revenue: SIGHT's revenue (39.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SIGHT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has GenSight Biologics performed over the past 5 years?
-30.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SIGHT has high quality earnings.
Growing Profit Margin: SIGHT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SIGHT is unprofitable, and losses have increased over the past 5 years at a rate of -30.2% per year.
Accelerating Growth: Unable to compare SIGHT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SIGHT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: SIGHT has a negative Return on Equity (-255.34%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is GenSight Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: SIGHT's short term assets (€25.2M) exceeds its short term liabilities (€8.7M)
Long Term Liabilities: SIGHT's short term assets (€25.2M) exceeds its long term liabilities (7.0M)
Debt to Equity History and Analysis
Debt Level: SIGHT's debt to equity ratio (23.1%) is considered satisfactory.
Reducing Debt: SIGHT's debt to equity ratio has increased from 2.3% to 23.1% over the past 5 years.
Balance Sheet
Inventory Level: SIGHT has a low level of unsold assets or inventory.
Debt Coverage by Assets: SIGHT's debt is covered by short term assets (assets are 7.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SIGHT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SIGHT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -21.6% each year
Next Steps
Dividend
What is GenSight Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate SIGHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SIGHT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SIGHT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SIGHT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SIGHT's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
What is the CEO of GenSight Biologics's salary, the management and board of directors tenure and is there insider trading?
3.2yrs
Average management tenure
CEO
Bernard Gilly (62yo)
7.8yrs
Tenure
€628,518
Compensation
Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He is Independent Chairman at EyeTechCare SA. He serves as President and Chairman of the Board at ChronoLife SAS. He co-founded Fovea Pharmaceutical ...
CEO Compensation Analysis
Compensation vs Market: Bernard's total compensation ($USD696.42K) is above average for companies of similar size in the French market ($USD158.33K).
Compensation vs Earnings: Bernard's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.2yrs
Average Tenure
Experienced Management: SIGHT's management team is considered experienced (3.2 years average tenure).
Board Age and Tenure
7.6yrs
Average Tenure
64yo
Average Age
Experienced Board: SIGHT's board of directors are considered experienced (7.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.1%.
Management Team
Bernard Gilly (62yo)
Co-Founder
- Tenure: 7.8yrs
- Compensation: €628.52k
José-Alain Sahel
Scientific Founder
- Tenure: 0yrs
Barrett Katz
Consultant
- Tenure: 2.1yrs
Connie Cepko
Scientific Founders & Member of Scientific Advisory Board
- Tenure: 7.6yrs
Botond Roska
Scientific Founder & Chairman of Scientific Advisory Board
- Tenure: 0yrs
Jean Bennett
Scientific Founder & Vice Chairman of Scientific Advisory Board
- Tenure: 0yrs
Luk Vandenberghe
Scientific Founder & Member of Scientific Advisory Board
- Tenure: 7.6yrs
Serge Picaud
Scientific Founder & Member of Scientific Advisory Board
- Tenure: 7.6yrs
Thomas Gidoin (36yo)
Chief Financial Officer
- Tenure: 4.3yrs
Julio Benedicto
Vice President of Marketing
- Tenure: 1.8yrs
Board Members
Mike Wyzga (64yo)
Independent Chairman of the Board
- Tenure: 3.7yrs
- Compensation: €165.35k
Bernard Gilly (62yo)
Co-Founder
- Tenure: 7.8yrs
- Compensation: €628.52k
Peter Goodfellow (68yo)
Independent Director
- Tenure: 0yrs
- Compensation: €60.00k
José-Alain Sahel
Scientific Founder
- Tenure: 0yrs
Connie Cepko
Scientific Founders & Member of Scientific Advisory Board
- Tenure: 7.6yrs
Botond Roska
Scientific Founder & Chairman of Scientific Advisory Board
- Tenure: 0yrs
Jean Bennett
Scientific Founder & Vice Chairman of Scientific Advisory Board
- Tenure: 0yrs
Luk Vandenberghe
Scientific Founder & Member of Scientific Advisory Board
- Tenure: 7.6yrs
Serge Picaud
Scientific Founder & Member of Scientific Advisory Board
- Tenure: 7.6yrs
Ernst Bamberg
Member of Scientific Advisory Board
- Tenure: 7.6yrs
Company Information
GenSight Biologics S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: GenSight Biologics S.A.
- Ticker: SIGHT
- Exchange: ENXTPA
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €34.864m
- Shares outstanding: 28.81m
- Website: https://www.gensight-biologics.com
Number of Employees
Location
- GenSight Biologics S.A.
- 74, rue du Faubourg Saint-Antoine
- Paris
- Ile-de-France
- 75012
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| G49N | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jul 2016 |
| SIGHT | ENXTPA (Euronext Paris) | Yes | Ordinary Shares | FR | EUR | Jul 2016 |
| 0RIM | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jul 2016 |
| SIGHTP | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jul 2016 |
| GSGT.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jul 2016 |
Biography
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and ce ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/19 22:00 |
| End of Day Share Price | 2019/11/19 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.